Latest Amniocentesis Stories

Stem Cells Heal Damaged Intestinal Tissue In Premature Babies

2013-03-25 08:16:18

Lawrence LeBlond for redOrbit.com - Your Universe Online Researchers studying stem cells removed from amniotic fluid have found a possible role the cells have on healing damage caused by necrotizing enterocolitis (NEC), a severe inflammation that can destroy tissues in the gut and lead to major organ failure. The findings, published in the journal Gut, are based on early animal tests that reveal healing and an increase in survival. The researchers say the evidence could lead to a new...

MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference

2013-03-14 08:28:23

KENNESAW, Ga., March 14, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Canaccord Genuity Musculoskeletal Conference in Chicago. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on...

Presence Of Intra-Amniotic Debris A Risk For Early Preterm Birth In First Pregnancy

2013-02-11 13:46:10

In a study to be presented on February 14 between 8 a.m. and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, California, researchers will report findings suggesting an increased risk of early (less than 35 weeks) preterm birth when intra-amniotic debris is present in nulliparous women with a short cervix. The babies born to women with debris had worse outcomes than those born to women without debris, likely due to the...

MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts

2013-02-11 08:25:04

KENNESAW, Ga., Feb. 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four new issued patents related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,357,403, "Placental Tissue Grafts," with a grant date of January 22, 2013. The U.S...

Verinata Health Publishes Proof-of-Concept Data Showing Non-Invasive Fetal Karyotype Equivalent to Invasive Procedures

2013-01-10 12:23:19

REDWOOD CITY, Calif., Jan. 10, 2013 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced that its proprietary prenatal technology can detect fetal subchromosomal abnormalities non-invasively from maternal blood. These proof-of-concept data show that Verinata's proprietary approach together with deep massively parallel sequencing (MPS) is able to produce a non-invasive fetal karyotype equivalent to that provided by...

The Leading Edge Of Medical Innovation: New Prenatal Genetic Tests Use Mom's Blood To Learn About Her Baby

2012-12-13 12:24:30

What Parents Need To Know About These New Tests NEW YORK, Dec. 13, 2012 /PRNewswire-USNewswire/ -- New prenatal tests can give some parents piece of mind - sooner and with greater accuracy and less risk of miscarriage than current tests - that the baby they're expecting doesn't have a disorder. The new tests, which use fetal DNA suspended in the mother's blood, can test for chromosomal disorders such as Down syndrome (trisomy 21) and trisomy 18, and Rh blood incompatibility. They...

MiMedx Issued First U.S. Patent for Placental Tissue Grafts

2012-12-06 12:28:26

KENNESAW, Ga., Dec. 6, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of the Company's first issued patent related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,323,701, "Placental Tissue Grafts", originally filed in...

MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum

2012-11-20 12:29:45

KENNESAW, Ga., Nov. 20, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today that it will present at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York City. William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on December 4th, at...

Verinata Health's verifi® prenatal test Expanded To Include The Most Common Sex Chromosome Abnormalities

2012-11-06 08:28:21

REDWOOD CITY, Calif., Nov. 6, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced that it is expanding the verifi® prenatal test capabilities to include detection of the most common sex chromosome abnormalities. Clinicians will now be able to select the sex chromosomes option on the verifi® test to access this addition. (Logo: http://photos.prnewswire.com/prnh/20120425/SF94380LOGO) Beginning December 3,...

MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference

2012-09-20 06:31:50

KENNESAW, Ga., Sept. 20, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today that it will present at the Craig-Hallum 3(rd) Annual Alpha Select Conference in New York City. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled...